Target-Directed Approaches for Screening Small Molecules against RNA Targets.
Haniff HS, Knerr L, Chen JL, Disney MD, Lightfoot HL.
SLAS Discov. 2020 Sep;25(8):869-894. doi: 10.1177/2472555220922802. Epub 2020 May 18.
Chasing molecular glue degraders: screening approaches.
Domostegui A, Nieto-Barrado L, Perez-Lopez C, Mayor-Ruiz C.
Chem Soc Rev. 2022 Jul 4;51(13):5498-5517. doi: 10.1039/d2cs00197g.
Emerging Targets in Non-Small Cell Lung Cancer.
Liu L, Soler J, Reckamp KL, Sankar K.
Int J Mol Sci. 2024 Sep 18;25(18):10046. doi: 10.3390/ijms251810046.
The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem.
Corre I, Verrecchia F, Crenn V, Redini F, Trichet V.
Cells. 2020 Apr 15;9(4):976. doi: 10.3390/cells9040976.
Genome engineering with zinc-finger nucleases.
Carroll D.
Genetics. 2011 Aug;188(4):773-82. doi: 10.1534/genetics.111.131433.
Targeting thromboinflammation in antiphospholipid syndrome.
Salet DM, Bekkering S, Middeldorp S, van den Hoogen LL.
J Thromb Haemost. 2023 Apr;21(4):744-757. doi: 10.1016/j.jtha.2022.12.002. Epub 2022 Dec 22.
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T.
Signal Transduct Target Ther. 2021 Feb 20;6(1):72. doi: 10.1038/s41392-020-00449-4.
Targeted Drug Delivery: Trends and Perspectives.
Ashique S, Sandhu NK, Chawla V, Chawla PA.
Curr Drug Deliv. 2021;18(10):1435-1455. doi: 10.2174/1567201818666210609161301.
Rethinking target discovery in polygenic diseases.
Flordellis CS, Manolis AS, Paris H, Karabinis A.
Curr Top Med Chem. 2006;6(16):1791-8. doi: 10.2174/156802606778194226.
Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer.
Stuchbery R, Kurganovs NJ, McCoy PJ, Nelson CC, Hayes VM, Corcoran NM, Hovens CM.
Curr Cancer Drug Targets. 2015;15(5):394-405. doi: 10.2174/1568009615666150416113453.
